Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer (SITC) 39th Annual MeetingWatch the "What This Means" video hereFRAMINGHAM, MA / ACCESSWIRE / November 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced that announced that Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic participated in a Virtual Investor "What This Means" segment.

Data presented at the AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in CancerResults bolster Company's rationale for incorporating DNase I as an adjunctive treatment to improve therapeutic responses in patients undergoing CAR T cell therapy FRAMINGHAM, MA / ACCESSWIRE / November 21, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced the presentation of preclinical data investigating the potential of co-administration of deoxyribonuclease I (DNase I) with chimeric ant

Establishing growing body of preclinical data evaluating the DNase-based oncology platform across a number of high-value oncology indicationsOngoing progress towards first in human clinical study for locally advanced or metastatic solid tumorsStrategic focus on exploratory investigator-initiated studies with institutional partnersEnded the quarter with $6.8 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / November 13, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the third quarter of

Data presented at Society for Immunotherapy of Cancer (SITC) 2024Systemic DNase I combined with

Company is advancing DNase-based oncology program towards clinical proof-of-concept studies in multiple indications FRAMINGHAM, MA / ACCESSWIRE / November 7, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced it has extended its previously announced Research Funding and Option Agreement (the "Agreement") with The Scripps Research Institute ("TSRI") to advance the development of the Company's program on the combination of systemic DNase and CAR T-cell therapies. Xenetic's systemic DNase I candidate is undergoing precl

FRAMINGHAM, MA / ACCESSWIRE / October 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6-10, 2024, in Houston, Texas and virtually.Details of the presentation are as follows:Title: DNase I Targeting of Neutrophil Extracellular Traps Improves CTLA-4 Immune Checkpoint blockade in Models of MSS/MMRp CRCAbstract Number: 765Presenter: Reid Bissonnette, Ph.D., Executive Cons

Xenetic to supply recombinant DNase I to Tokyo Medical University for evaluation as a treatment of Ewing sarcoma in unique preclinical model FRAMINGHAM, MA / ACCESSWIRE / October 17, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced it has entered into a Materials Transfer Agreement with Tokyo Medical University to advance the development of its systemic DNase program.Under the terms of the agreement, Professor Takuro Nakamura of the Department of Experimental Pathology, Institute of Medical Science at Tokyo Medical

Ongoing preclinical studies with data expected before year endFocus on demonstration of DNase-based oncology program in clinical proof-of-concept studies in multiple indicationsEnded the quarter with $7.3 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / August 14, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the second quarter of 2024. "We remain confident in the potential of our DNase-based oncology platform and continue to advance our preclinical studies with data expected before

Company's Board of Directors Appoint James F. Parslow to Interim Chief Executive Officer FRAMINGHAM, MA / ACCESSWIRE / May 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced the appointment of James Parslow, the Company's Chief Financial Officer, as interim Chief Executive Officer, effective May 16, 2024."I am a strong believer in the potential of our innovative immune-oncology technologies addressing hard-to-treat cancers. This management change will allow us to focus our resources on driving our pipeline toward

Ongoing preclinical studies with multiple data readouts expected throughout remainder of 2024Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumorsEnded the quarter with $7.8 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / May 10, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the first quarter of 2024 and provided a business update."We have initiated several

4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)

4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)

3 - Xenetic Biosciences, Inc. (0001534525) (Issuer)

4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)

4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)

4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)

4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)

4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)

4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)

4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)

Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.78) per share which beat the analyst consensus estimate of $(0.79) by 1.27 percent. The company reported quarterly sales of $510.817 thousand which missed the analyst consensus estimate of $650.000 thousand by 21.41 percent. This is a 15.69 percent decrease over sales of $605.844 thousand the same period last year.

Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.77) per share which beat the analyst consensus estimate of $(0.87) by 11.49 percent. This is a 23 percent increase over losses of $(1.00) per share from the same period last year. The company reported quarterly sales of $671.96 thousand which missed the analyst consensus estimate of $680.00 thousand by 1.18 percent. This is a 37.99 percent increase over sales of $486.97 thousand the same period last year.

Xenetic Biosciences (NASDAQ:XBIO) reported quarterly earnings of $0.77 per share which beat the analyst consensus estimate of $(0.87) by 188.51 percent. This is a 177 percent increase over losses of $(1.00) per share from the same period last year. The company reported quarterly sales of $671.96 thousand which missed the analyst consensus estimate of $680.00 thousand by 1.18 percent. This is a 37.99 percent increase over sales of $486.97 thousand the same period last year.

- Company building growing body of preclinical data to guide pathway to first in human trial for DNase-based oncology platform

Gainers PHAXIAM Therapeutics (NASDAQ:PHXM) shares moved upwards by 22.1% to $5.13 during Tuesday's regular session. The market value of their outstanding shares is at $31.1 million. Travere Therapeutics (NASDAQ:TVTX) stock moved upwards by 20.66% to $7.59. The market value of their outstanding shares is at $570.3 million. MSP Recovery (NASDAQ:LIFW) stock rose 18.99% to $4.0. The market value of their outstanding shares is at $57.2 million. Xenetic Biosciences (NASDAQ:XBIO) stock rose 17.84% to $4.16. The company's market cap stands at $6.4 million. Cerevel Therapeutics Hldg (NASDAQ:CERE) shares moved upwards by 16.28% to $36.98. The company's market cap stands at $6.6 billion. Kala Bio

Xenetic Biosciences (NASDAQ:XBIO) reported its Q3 earnings results on Friday, November 10, 2023 at 08:35 AM. Here's what investors need to know about the announcement. Earnings Xenetic Biosciences beat estimated earnings by 38.39%, reporting an EPS of $-0.69 versus an estimate of $-1.12. Revenue was up $196 thousand from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.44 which was followed by a 0.83% increase in the share price the next day. To track all earnings releases for Xenetic Biosciences visit their earnings calendar here. This article was generated by Benzinga's automated content engine and reviewed by an editor.

Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(1.12) by 38.39 percent. This is a 15 percent decrease over losses of $(0.60) per share from the same period last year. The company reported quarterly sales of $611.17 thousand which beat the analyst consensus estimate of $460.00 thousand by 32.86 percent. This is a 47.54 percent increase over sales of $414.25 thousand the same period last year.

Gainers Evelo Biosciences (NASDAQ:EVLO) stock increased by 60.7% to $0.19 during Tuesday's pre-market session. The company's market cap stands at $21.6 million. DICE Therapeutics (NASDAQ:DICE) shares moved upwards by 38.07% to $46.74. The market value of their outstanding shares is at $2.2 billion. Nuwellis (NASDAQ:NUWE) stock moved upwards by 34.81% to $3.95. The company's market cap stands at $4.7 million. Biofrontera (NASDAQ:BFRI) shares increased by 29.54% to $0.57. The company's market cap stands at $15.2 million. Innovative Eyewear (NASDAQ:LUCY) shares increased by 25.11% to $2.74. The market value of their outstanding shares is at $23.0 million. Cano Health (NYSE:CANO) stock inc

HC Wainwright has downgraded Xenetic Biosciences Inc (NASDAQ:XBIO) from Buy to Neutral, citing pending clinical path visibility. In the Q1 earnings release, the company announced continued progress with the DNase-based oncology program toward Phase 1 study for pancreatic carcinoma and other locally advanced or metastatic solid tumors. Xenetic announced a one-for-ten reverse stock split, the second reverse split in four years. The analyst noted that the split is not necessarily concerning amid this volatile healthcare market. But the analyst is moving to the sidelines due to volatile markets combined with a lack of catalysts to shore up the shares. The analyst has downgraded based on th